Journal of the American Medical Directors Association, Journal Year: 2022, Volume and Issue: 24(1), P. 27 - 28
Published: Nov. 11, 2022
Language: Английский
Vaccines, Journal Year: 2022, Volume and Issue: 10(5), P. 798 - 798
Published: May 18, 2022
A prime-boost strategy of COVID-19 vaccines brings hope to limit the spread SARS-CoV-2, while immunogenicity is waning over time. Whether a booster dose vaccine needed has become widely controversial issue. However, no published meta-analysis focused on Therefore, this study assessed and safety different combinations vaccinations. Electronic databases including PubMed, Cochrane Library, Embase, medRxiv, Wanfang CNKI were used retrieve original studies. total 28 studies, 9 vaccinations 5870 subjects included in meta-analysis, random effect models estimate pooled safety. The immunity against after prime vaccination waned time, especially populations primed with inactivated vaccines, which seropositive rate antibodies was only 28% (95% CI: 17-40%). Booster could significantly increase antibody responses, heterologous immunization more effective than homologous (neutralization titers: 1.65 vs. 1.27; anti-RBD IgG: 1.85 1.15); particular, combination inactivated-mRNA had highest responses MRAW = 3.64, 95% 3.54-3.74; 3.73, 3.59-3.87). Moreover, compared initial two doses did not induce additional or severe adverse events. administration effectively recalled specific immune SARS-CoV-2 increased levels, immunization. Considering long-term equity, we suggest that now, individuals require dose.
Language: Английский
Citations
31
Drugs in Context, Journal Year: 2023, Volume and Issue: 12, P. 1 - 11
Published: Feb. 6, 2023
The SARS-CoV-2 pandemic is the most globally impacting health issue our world has faced over last century. As of January 7, 2022, around 300 million cases have been reported worldwide, with 5 deaths. infection causes a hyperactive host immune response leading to an excessive inflammatory reaction release many cytokines - cytokine storm commonly noticed in acute respiratory distress syndrome, sepsis and fulminant multiorgan failure. Since beginning pandemic, scientific medical community worked on therapeutic procedures that interfere exaggerated response. Thromboembolic complications are widespread patients who critically ill COVID-19. Anticoagulant therapy was initially considered cornerstone hospitalized even early post-discharge period; however, later trials aborted clinical benefits except for suspicion or confirmed thrombosis. Immunomodulatory therapies still crucial moderate severe Immunomodulator include various medications from steroids hydroxychloroquine, tocilizumab Anakinra. Anti-inflammatory agents, vitamin supplements antimicrobial had initial encouraging evidence, but there limited data review. Convalescent plasma, immunoglobulins, eculizumab, neutralizing IgG1 monoclonal antibodies remdesivir positively impacted inpatient mortality hospital length stay. Eventually, wide population vaccination proven be best tool overcome help humanity return regular life. Many vaccines strategies used since December 2020. This review discusses how progressed surged, summarizes safety efficacy light recent evidence.
Language: Английский
Citations
15
Immunity & Ageing, Journal Year: 2025, Volume and Issue: 22(1)
Published: Jan. 2, 2025
As older age and having certain comorbidities can influence humoral responses to vaccination, we studied antibody after the COVID-19 booster campaigns in nursing home (NH) residents. In a two year longitudinal study with Dutch NH residents (n = 107), aged 50 years over, monitored serum prior vaccination third, fourth BNT162b2 (wild-type; WT), bivalent (WT/OMI BA.1) fifth vaccine. Data on vaccinations, infections, comorbidities, and, for some participants, clinical symptoms infection were obtained questionnaires. compared of BNT162b2-vaccinated, healthier community-dwelling adults 32) from general population. The vaccinations substantially increased anti-WT anti-Omicron SARS-CoV-2 Spike S1 (S1) protein receptor binding domain (RBD)-antibody concentrations This resulted comparable levels between infection-naïve infected residents, decline treatment duration symptom severity SARS-CoV-2-infected Between one twelve months dose, BA.1 waned faster than those against WT strain. upheld Omicron SARS-CoV-2. This, addition less virulent circulating strains, decreased durations Boosting this vulnerable group should, therefore, be continued prevent waning immunity achieve sufficient protection especially newly emerging variants concern.
Language: Английский
Citations
0
Journal of the American Geriatrics Society, Journal Year: 2022, Volume and Issue: 70(9), P. 2552 - 2560
Published: April 29, 2022
Duration of post-vaccination protection against COVID-19 in nursing home (NH) residents is a critical issue. The objective this study was to estimate the duration IgG(S) response mRNA BNT162b2 vaccine NH with (COV-Yes) or without (COV-No) history SARS-CoV-2 infection.A 574 COV-Yes and COV-No were included 2 cohorts: Main (n = 115, median age 87 years) Confirmatory 459, 89 years). quantification carried out at three different time points following vaccine: (1st) seven (2nd) months after 2nd dose, 1 month 3rd dose (3rd quantification) cohort, twice (2nd 3rd) cohort. seroneutralization capacity according also measured subgroup patients.Neutralization strongly correlated levels (R2 :76%) any difference between groups for same IgG(S). After assumed robust (IgG(S) >264 BAU/ml) two-fold higher vs. group: 12.60 (10.69-14.44) versus 5.76 (3.91-8.64) months, advantage mainly due titers secondary slower decay over time. estimated 11.87 (9.88-14.87) 8.95 (6.85-11.04) months. These results similar both cohorts.In old subjects living NH, infection provides clear magnitude high dose. Importantly, induces much more pronounced than subjects, effect which should be able ensure prolonged severe forms these subjects.
Language: Английский
Citations
16
Clinical Immunology, Journal Year: 2025, Volume and Issue: 276, P. 110491 - 110491
Published: April 4, 2025
Language: Английский
Citations
0
Journal of the American Medical Directors Association, Journal Year: 2022, Volume and Issue: 24(2), P. 140 - 147.e2
Published: Dec. 7, 2022
Language: Английский
Citations
11
Clinical Rheumatology, Journal Year: 2023, Volume and Issue: 42(9), P. 2485 - 2490
Published: May 27, 2023
Language: Английский
Citations
3
HemaSphere, Journal Year: 2022, Volume and Issue: 6(7), P. e747 - e747
Published: June 21, 2022
The waning of humoral immunity post coronavirus disease 2019 (COVID-19) vaccination necessitated the implementation booster doses. BNT162b2 administered as first and second dose following initial full leads to significant responses against severe acute respiratory syndrome 2 (SARS-CoV-2).1,2 In Israel, a third vaccine shot significantly reduced risk SARS-CoV-2 among 1650 triple-vaccinated health care workers compared with 278 double-vaccinated individuals.3 Importantly, improves protection COVID-19 hospitalizations.4 Recently, fourth has been offered in many developed countries maintain an adequate level COVID-19.2 However, optimal time interval between doses remains under question. purpose this study was examine kinetics neutralizing antibodies (NAbs) after mRNA (Pfizer-BioNTech) for period up 6 months (booster dose). potential impact gender, age, body mass index (BMI) on NAbs also investigated. This enrolled 100 healthy participants, all whom were vaccinated 3 vaccine. measured day (immediately before vaccination), 1 week later (day 8), (ie, 22), weeks 36), month, months, 9 dose. measurements performed at It should be mentioned that none participants tested positive COVID-19; therefore, values reflect immunization dynamics. using Food Drug Administration-approved techniques. To detect blood, cPass Detection Kit (GenScript, Piscataway, NJ) used test antibody-mediated suppression receptor-binding domain binding human host receptor angiotensin-converting enzyme 2. After venipuncture, serum isolated within 4 hours refrigerated –80°C until measurement. Parallel experiments stored samples from same donor. Participants had over 18 years able sign informed consent form, eligible national program. Individuals receiving immunosuppressive medications, well those active malignancies and/or end-stage renal disease, excluded. Subject data kept confidential accordance Basic Data Protection Regulation (Regulation 2016/679 European Parliament 2016). prevent identification patients, names immediately removed replaced by random number. Alexandra Hospital Ethics Committee approved Declaration Helsinki International Conference Harmonization Good Clinical Practice. analysis included both descriptive statistics (eg, median, mean, variability estimates) statistical group comparisons. Prior comparisons, Shapiro-Wilk criterion normality distributions. cases study, variables titers) found deviate distribution, so nonparametric methods used. Independent 2-group analyses men versus women) Mann-Whitney U test. Pairwise comparisons points Wilcoxon Analysis more than independent groups Kruskal-Wallis significance set 5%, result considered if estimated P value below level. All implemented Python v.3.9.2. Overall, study. median age 51 years, BMI 26.0 kg/m2, male-to-female ratio 1:1. Figure shows 1, 3, month 3rd [M1P3D], [M3P3D], [M6P3D], respectively). depicts percent inhibition days 8, 22 (D36), (D50), (M3), (M6), (M9) Visual inspection levels increase then decrease each dose, is very rapid, whereas much slower results Previous studies have shown response sustained least which may prolonged nursing home residents.5–7 Special populations such patients who undergone kidney transplant present antibody prioritized additional doses.8 dialysis or prior stem cell allogeneic persistent dose.9,10Figure 1.: Inhibition (percentage) (Pfizer-BioNTech). points: (D1), wk (D22) mo addition, (M1P3D), (M3P3D), (M6P3D) box plot boundaries show quartiles while superimposed dots represent individual inhibition. asterisk (*) indicates statistically difference (P < 0.05) highlighted (with arrow) case M6P3D. M1P3D = dose; M3P3D M6P3D antibodies; 2.Because titers made reference values. 95.5%, lower (97.2%) (97.8%). These differences (M6P3D M3P3D, M1P3D) 0.001). it interesting compare inhibitory activity similar M6). noteworthy remained high (95.5%) M6 (57.3%). As expected, proved worth noting comparable only (median 96.5%) (96.3%) vaccination; 0.250 0.529 comparison D36 D50, respectively. other cases, higher (D1, D8, D22, M3, M6, M9) (M1P3D, M3P3D) abovementioned points, reflected proportions moderate, high, protection. Specifically, 96% subjects above 50% 75%, estimating they moderately highly protected. One vaccination, corresponding percentages 100% cases. Interestingly, 60% greater 20% managed enter range. A further conducted respect gender uncover possible development no any point; 0.804, 0.972, 0.414 M1P3D, M6P3D, Thus, did not affect degree decline Similarly, influence evaluated. Subjects divided into according namely ≥51 <51 years. Again, found, neither nor 0.301, 0.860, 0.871, Another key predictive factor production Omicron variant dose.1 Finally, effect examined. 26, quarter less 23 another 25% 28.9. Application resulted 0.433). noted relatively small population led underpowered subgroup analyses. conclusion, these indicate individuals even BNT162b2. Our advocate extended shorter can immunocompromised elderly, depending epidemic ACKNOWLEDGMENTS We thank Mrs Ioanna Charitaki, RN; Zoi Evangelakou, MSc; Despoina D. Gianniou, Sentiljana Gumeni, PhD; Nikoletta-Aikaterini Kokkali, Christine-Ivy Liacos, Maria S. Manola, Nefeli Mavrianou, Eleni-Dimitra Papanagnou, Mr Dimitrios Patseas, Stamatia Skourti, administrative, technical, material support. IEMBITHEK (Greece) partially funding participants. AUTHOR CONTRIBUTIONS IPT, MAD, ET participated research design. IN-S, VK, writing article. ADS, MG, HA, PM, performance research. contributed new reagents analytic tools. analysis. authors reviewed provided approval final draft submission. DISCLOSURES HemaSphere editor. relevant conflicts interest disclose.
Language: Английский
Citations
5
Aging Clinical and Experimental Research, Journal Year: 2022, Volume and Issue: 34(10), P. 2577 - 2584
Published: Sept. 21, 2022
Nursing home (NH) residents suffered the greatest impact of COVID-19 pandemic. Limited data are available on vaccine-induced immunity and protection ensured by a prior infection in this population. The present study aims to monitor antibody levels their persistence over 6-month period NH according history SARS-CoV-2 infection. We measured anti-trimeric Spike IgG sample 395 from 25 NHs 6 Italian Regions at enrolment (prior first dose vaccine, T0) then after 2 (T1) months (T2) following vaccine dose. All participants received mRNA vaccines (BNT162b2 or mRNA-1273). Analyses were performed using log-transformed values concentrations geometric means (GM) calculated. Superior humoral was induced with previous (T0: GM 186.6 vs. 6.1 BAU/ml, p < 0.001; T1: 5264.1 944.4 T2: 1473.6 128.7 0.001). Residents receiving two doses presented significantly higher concentration T1 T2. A longer interval between vaccination associated better response time. In frail residents, vaccination. Number relevant parameters determining immunity. These findings provide important information plan future immunization policies disease prevention strategies highly vulnerable
Language: Английский
Citations
5
Aging Clinical and Experimental Research, Journal Year: 2023, Volume and Issue: 35(8), P. 1771 - 1778
Published: May 30, 2023
Language: Английский
Citations
2